Tevogen Bio Holdings INC 8-K filings

Tevogen Bio Holdings Inc. has filed certificates of designation for Series A and B preferred stock, securing an $8 million investment and addressing prior liabilities.

Tevogen Bio Holdings Inc. has adopted a new Code of Business Conduct and Ethics, effective February 14, 2024, to ensure ethical and legal standards across the company.

Tevogen Bio Holdings finalized a business combination, secured an $8 million investment through a Series A Preferred Stock offering, and restructured over $4.2 million in liabilities.

Tevogen Bio Inc. has entered into a $10 million convertible promissory note agreement and subsequently amended it to facilitate a potential SPAC transaction and extend the maturity date.

Semper Paratus Acquisition Corporation shareholders have approved the proposed business combination with Tevogen Bio, paving the way for the merger to be completed.

Semper Paratus Acquisition Corporation has filed a supplement to its proxy statement, announcing the planned listing of Tevogen Bio Holdings Inc. on the Nasdaq Stock Market instead of the NYSE American.